Type 2 DiabetesNCT05001815
CSII Versus MDI in Pregnant Women With Type 2 Diabetes
A study testing Continuous subcutaneous insulin infusion (CSII) and Multiple daily insulin injection (MDI) in people with Type 2 Diabetes and Pregnancy in Diabetic, run by Peking University Third Hospital at 1 site in China.
Trial summary
The primary objective of the study is to determine if continuous subcutaneous insulin infusion (CSII) can improve glycemic control in women with type 2 diabetes (T2D) who are pregnant. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Type 2 Diabetes, Pregnancy in Diabetic
- What is being tested?
- Continuous subcutaneous insulin infusion (CSII) and Multiple daily insulin injection (MDI)
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 15 Dec 2021to 1 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women aged 18 to 40 years old
- Patients with confirmed history of T2D or patients who are newly diagnosed with T2D by oral glucose tolerance test (OGTT) during pregnancy (diagnostic criteria refer to ADA 2020 guideline for T2D).
- Women with singleton pregnancy at 4 to 20 weeks of gestation, whose blood glucose fails to achieved glucose target after adequate lifestyle intervention with or without the prescription of basal insulin (i.e. fasting blood glucose above 5.3 mmol/L, or one hour postprandial blood glucose above 7.8 mmol/L, or two hour postprandial blood glucose above 6.7 mmol/L), and need to start intensive insulin therapy (MDI or insulin pump) according to the evaluation of endocrinologists.
- Patients who are willing be followed up by the Third Hospital of Peking University in the whole process of pregnancy until 6 weeks of postpartum, and promise that they will provide the results of relative prenatal examinations and perinatal medical records if they are transferred to another hospital for special reasons.
- Patients who can pass the compliance test and agree to conduct self-monitoring of blood glucose (SMBG) at least 7 times a day during pregnancy.
- Patients who volunteer to participate the trial and agree to sign informed consent.
Who cannot join
- Patients with T1D, special type of diabetes and gestational diabetes.
- Patients who have received intensive insulin therapy (MDI or insulin pump) or premixed fixed doses of insulin before enrollment in this trial.
- Patients who refuse to use insulin pump or CGM devices.
- Patients who are not recommended by obstetrician to continue their pregnancy due to comorbidity and high risk of pregnancy. The comorbidities include but not limited to the following diseases: proliferative retinopathy, chronic kidney disease (eGFR less than 60 ml /min/1.73 with or without heavy proteinuria), known coronary heart disease and cerebrovascular disease, autoimmune disease, other diseases requiring exogenous glucocorticoid or immunosuppressive therapy.
- Patients who received inpatient psychiatric treatment within 6 months before enrollment or still using psychiatric drugs.
- Participated in other intervention studies.
Trial locations and contacts
1 site in 1 country.
China1 site
Peking University Third Hospital
Beijing, Beijing Municipality, 100191
Wang Haining, PhD
About this study
Official title: Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injection in Pregnant Women With Type 2 Diabetes: A Single-center Open Label Randomized Controlled Trial
The primary objective of the study is to determine if continuous subcutaneous insulin infusion (CSII) can improve glycemic control in women with type 2 diabetes (T2D) who are pregnant.
Read the detailed description
In women with diabetes, hyperglycemia is associated with increased rates of maternal and fetal adverse outcomes. Mothers are at increased risk of preeclampsia, deterioration of proteinuria and caesarean sections. Infants of mothers with diabetes have increased rates of congenital anomalies, premature delivery, macrosomia, stillbirth and NICU admissions, as well as increased risks of shoulder dystocia, birth injury, hypoglycemia, hyperbilirubinemia, respiratory distress syndrome, asphyxia and death in the neonatal period. Several studies have shown that pregnancy outcomes can be improved along with better glycemic control. Theoretically CSII could achieve better glycemic control due to its flexibility in adjusting both basal rate and bolus insulin infusion. Several randomized controlled studies have compared the ability of CSII with multiple daily injection (MDI) in glycemic control and improvement of pregnancy outcomes in patients with type 1 diabetes (T1D). However, there is a lack of similar studies in women with T2D. We hypothesize that CSII will assist women with T2D achieve better glycemic control during pregnancy compared to MDI users.
- Conditions
- Type 2 Diabetes, Pregnancy in Diabetic
- Being tested
- Continuous subcutaneous insulin infusion (CSII), Multiple daily insulin injection (MDI)
- Keywords
- type 2 diabetes, pregnancy, continuous subcutaneous insulin infusion, multiple daily injection
- Medical subject headings
- Diabetes Mellitus, Type 2, Pregnancy in Diabetics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous subcutaneous insulin infusion (CSII)Device
The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
Multiple daily insulin injection (MDI)Device
Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
| Study group | Role | What they receive |
|---|---|---|
| Continuous subcutaneous insulin infusion (CSII) | Experimental | Patients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices. Receives: Device: Continuous subcutaneous insulin infusion (CSII) |
| Multiple daily insulin injection (MDI) | Active comparator | Patients with indications will receive traditional multiple daily insulin injection (MDI) treatment. Receives: Device: Multiple daily insulin injection (MDI) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time in range (TIR) at 24 weeks of gestation
Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 24 weeks of gestation among women with type 2 diabetes mellitus.
Measured: 24 weeks of gestation
Time in range (TIR) at 28 weeks of gestation
Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 28 weeks of gestation among women with type 2 diabetes mellitus.
Measured: 28 weeks of gestation
Time in range (TIR) at 34 weeks of gestation
Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 34 weeks of gestation among women with type 2 diabetes mellitus.
Measured: 34 weeks of gestation
Secondary outcomes (23)
Glycosylated hemoglobin (HbA1c) and glycosylated serum albumin
Glycosylated hemoglobin (HbA1c) and glycosylated serum albumin in meta-late phase of pregnancy.
Measured: 24, 28, 34 weeks of gestation and 6 weeks of postpartum
TIR calculated by patients' SMBG data
TIR calculated by patients' SMBG data at 4 weeks after randomization, and at 24, 28, 34 and 38 weeks of gestation.
Measured: At 4 weeks after randomization, and at 24, 28, 34 and 38 weeks of gestation
TAR and TBR
Time above range (TAR) and time below range (TBR) calculated by CGM data at 24, 28 and 34 weeks of gestation.
Measured: At 24, 28 and 34 weeks of gestation
Blood glucose fluctuation index
Mean amplitude of glucose excursion (MAGE), coefficient of variation (CV) and standard deviation (SD) calculated by CGM data recorded at 24, 28 and 34 weeks of gestation.
Measured: At 24, 28 and 34 weeks of gestation
The AUC of blood glucose within 24 hours before delivery
The area under curve (AUC) of peripheral blood glucose within 24 hours before delivery: (a) >7.8 mmol/l or 140 mg/dl (b)>6.7 mmol/l or 120 mg/dl (c) <3.5 mmol/L or <63 mg/dl (d) <2.8 mmol/L or <50 mg/dl.
Measured: Within 24 hours before delivery
Hypoglycemic events
(a)Episodes of severe hypoglycemia requiring assistance. (b)Episodes of mild-moderate episodes of hypoglycemia < 3.5mmol/L (mild) and < 2.8 mmol/L (moderate) from patients' SMBG data or from CGM data defined as AUC <3.5 mmol/L or AUC less than or equal to 2.8 mmol/L for 20 minutes duration. (c) Nocturnal hypoglycemia defined as glucose <3.5 (mild) and <2.8 (moderate) by SMBG or CGM between the hours of 23.00-07.00.
Measured: From randomization, up to 42 weeks of gestation
Insulin requirements
The total daily insulin dosage at randomization, 4 weeks after randomization, and 24, 28, 34 weeks of gestation as well as 6 weeks of postpartum.
Measured: 4 weeks after randomization, 24, 28, 34 weeks of gestation and 6 weeks of postpartum.
Hypertension during pregnancy
Hypertension during pregnancy (up to 42 weeks of gestation): Incidence of worsening of chronic hypertension, gestational hypertension, preeclampsia.
Measured: From randomization, up to 42 weeks of gestation
Caesarean sections at delivery
Incidence of caesarean section (primary and total)
Measured: At delivery
Gestational weight gain
Gestational weight gain: Absolute and relative weight gain at 24, 28, 34 weeks of gestation and 6 weeks of postpartum comparing to baseline (4-8 weeks of gestation at the time of enrollment)
Measured: 24, 28, 34 weeks of gestation and 6 weeks of postpartum
Maternal hospital stay
Length of hospital stay including admission for delivery and for other obstetric situations during pregnancy.
Measured: From admission to discharge from hospital due to delivery
Infant birthweight
Infant birthweight (at birth): Infant birthweight>90th centile using customized growth curves; infant birthweight<10th centile using customized growth curves; infant birthweight≥4000g or ≤2500g.
Measured: At delivery
Pregnancy loss
Including miscarriage, stillbirth and neonatal death (≤28 days of life).
Measured: From randomization, up to 28 days after delivery
Infant Outcomes (Gestational week of delivery)
Infant Outcomes (at birth): The incidence of preterm delivery (<37 weeks and early preterm <34 weeks) and post-term delivery (>42 weeks).
Measured: At birth
Infant Outcomes (Apgar score)
Infant Outcomes (at birth): Apgar score
Measured: At birth
Infant Outcomes (Up to first 7 days of infants' life)
The incidence of birth injury, shoulder dystocia, neonatal hypoglycemia with intravenous dextrose.
Measured: Up to first 7 days of infants' life
Infant Outcomes (Up to f first 7 days of life)
Incidence of hyperbilirubinemia, respiratory Distress Syndrome (RDS), NICU admission > 24 hours.
Measured: Up to first 7 days of infants' life
The composite endpoint of infants
The combined adverse outcomes of infants including miscarriage, stillbirth and neonatal death; Neonatal birth injury, shoulder dystocia, neonatal hypoglycemia (requiring intravenous glucose infusion), neonatal jaundice, neonatal respiratory distress syndrome (RDS) and more than 24 hours of treatment in NICU.
Measured: Up to first 7 days of infants' life
Questionnaires (WHO-5 physical and mental health index)
The score of World health organization (WHO)-5 physical and mental health index acquired from patients.
The WHO-5 scale (1998 version) was used to measure the patient's quality of life. The scale contains 5 items which initial points is 0-25. The initial points are multiplied by 4 to obtain the percentage points, ranging from 0 to 100,which are used to monitor possible changes in physical and mental health. 0 represents the worst possible quality of life, 100 represents the best possible quality of life, and a difference of 10% indicates significant changes.
Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-manage behavior scale)
The score of Self-manage behavior scale acquired from patients. Diabetes self-care behaviors includes a range of activities (e.g., eating diabetic food, exercising, glucose monitoring and taking medicine), which were evaluated by the Summary of Diabetes Self-Care Activities (SDSCA). SDSCA, compiled by Toobert in 2000, is an 8-likert scale containing 11 items belongs to 6 dimensions, could estimate general diet, special diet, physical activity, glucose monitoring, foot care and medicine compliance of patients with T2DM. The total scores range from 0 to 77, higher score means better diabetes self- care behaviors.
Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-efficacy scale for diabetes mellitus)
The score of self-efficacy scale for diabetes mellitus acquired from patients. Self-Efficacy for Diabetes (SED), a 5-Likert scale including 9 items, is used to measure patients' self-efficacy. The average score is 1-5 points, and the higher the average score, the higher the self-efficacy level of participants. The effectiveness and internal consistency of the Chinese version of SED are reliable, and the load factors of each factor are between 0.579-0.922.
Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-rated Anxiety Scale, SAS)
The score of Self-rated Anxiety Scale (SAS) acquired from patients. Self-Rating Anxiety Scale (SAS) is used to measure the degree of anxiety in patients. There are 20 items in total. The scores are divided into 4 levels, including 5 (items 5, 9, 13, 17, 19) reverse scoring items and 15 positive scoring items. Add the scores of the 20 items to get the rough score, then multiply it by 1.25 and take the integer part to get the standard score. The higher the standard score, the more serious the degree of anxiety.
Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-rated Depression Scale, SDS)
The score of Self-rated Depression Scale (SDS) acquired from patients. The Self-Rating Depression Scale (SDS) is used to measure the degree of depression in patients. There are 20 items in total, including 10 (items 2, 5, 6, 11, 12, 14, 16, 17, 18, and 20) reverse scoring items, and 15 positive scoring items. The depression severity index can be calculated by the cumulative score of each item divided by 80, which could reflect the degree of depression. The index range is 0.25-1.0, and the higher the index, the more severe the degree of depression.
Measured: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2021
- Study start15 Dec 2021 (estimated)
- Primary completion1 Aug 2023 (estimated)
- Study completion1 Oct 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by Peking University Third HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05001815
- Sponsor's protocol ID
- 2021NFM001
- Status last verified
- Jul 2021
- First submitted
- 26 Jul 2021
- Last updated
- 30 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Other researchers can contact the research group for IPD only for academic research, after the ethics committee re-evaluation and determination that the data transmission did not cause privacy disclosure to patients.
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injection in Pregnant Women With Type 2 Diabetes: A Single-center Open Label Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05001815
- Acronym / sponsor ID
- 2021NFM001
- Conditions
- Type 2 Diabetes, Pregnancy in Diabetic
- Keywords
- type 2 diabetes, pregnancy, continuous subcutaneous insulin infusion, multiple daily injection
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- 15 Dec 2021 (estimated)
- Primary completion
- 1 Aug 2023 (estimated)
- Study completion
- 1 Oct 2023 (estimated)
- First posted
- 12 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the study is to determine if continuous subcutaneous insulin infusion (CSII) can improve glycemic control in women with type 2 diabetes (T2D) who are pregnant.
Detailed description
In women with diabetes, hyperglycemia is associated with increased rates of maternal and fetal adverse outcomes. Mothers are at increased risk of preeclampsia, deterioration of proteinuria and caesarean sections. Infants of mothers with diabetes have increased rates of congenital anomalies, premature delivery, macrosomia, stillbirth and NICU admissions, as well as increased risks of shoulder dystocia, birth injury, hypoglycemia, hyperbilirubinemia, respiratory distress syndrome, asphyxia and death in the neonatal period. Several studies have shown that pregnancy outcomes can be improved along with better glycemic control. Theoretically CSII could achieve better glycemic control due to its flexibility in adjusting both basal rate and bolus insulin infusion. Several randomized controlled studies have compared the ability of CSII with multiple daily injection (MDI) in glycemic control and improvement of pregnancy outcomes in patients with type 1 diabetes (T1D). However, there is a lack of similar studies in women with T2D. We hypothesize that CSII will assist women with T2D achieve better glycemic control during pregnancy compared to MDI users.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Continuous subcutaneous insulin infusion (CSII) | Experimental | Device: Continuous subcutaneous insulin infusion (CSII)Patients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices. |
| Multiple daily insulin injection (MDI) | Active comparator | Device: Multiple daily insulin injection (MDI)Patients with indications will receive traditional multiple daily insulin injection (MDI) treatment. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Women aged 18 to 40 years old
- Patients with confirmed history of T2D or patients who are newly diagnosed with T2D by oral glucose tolerance test (OGTT) during pregnancy (diagnostic criteria refer to ADA 2020 guideline for T2D).
- Women with singleton pregnancy at 4 to 20 weeks of gestation, whose blood glucose fails to achieved glucose target after adequate lifestyle intervention with or without the prescription of basal insulin (i.e. fasting blood glucose above 5.3 mmol/L, or one hour postprandial blood glucose above 7.8 mmol/L, or two hour postprandial blood glucose above 6.7 mmol/L), and need to start intensive insulin therapy (MDI or insulin pump) according to the evaluation of endocrinologists.
- Patients who are willing be followed up by the Third Hospital of Peking University in the whole process of pregnancy until 6 weeks of postpartum, and promise that they will provide the results of relative prenatal examinations and perinatal medical records if they are transferred to another hospital for special reasons.
- Patients who can pass the compliance test and agree to conduct self-monitoring of blood glucose (SMBG) at least 7 times a day during pregnancy.
Key exclusion criteria (6 listed)
- Patients with T1D, special type of diabetes and gestational diabetes.
- Patients who have received intensive insulin therapy (MDI or insulin pump) or premixed fixed doses of insulin before enrollment in this trial.
- Patients who refuse to use insulin pump or CGM devices.
- Patients who are not recommended by obstetrician to continue their pregnancy due to comorbidity and high risk of pregnancy. The comorbidities include but not limited to the following diseases: proliferative retinopathy, chronic kidney disease (eGFR less than 60 ml /min/1.73 with or without heavy proteinuria), known coronary heart disease and cerebrovascular disease, autoimmune disease, other diseases requiring exogenous glucocorticoid or immunosuppressive therapy.
- Patients who received inpatient psychiatric treatment within 6 months before enrollment or still using psychiatric drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous subcutaneous insulin infusion (CSII)The CSII device used in this study has access to mobile phone, however, without CGM enhanced function | Device | Continuous subcutaneous insulin infusion (CSII) |
| Multiple daily insulin injection (MDI)Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection. | Device | Multiple daily insulin injection (MDI) |
Primary outcome
Time in range (TIR) at 24 weeks of gestation
Time frame: 24 weeks of gestation
Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 24 weeks of gestation among women with type 2 diabetes mellitus.
Time in range (TIR) at 28 weeks of gestation
Time frame: 28 weeks of gestation
Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 28 weeks of gestation among women with type 2 diabetes mellitus.
Time in range (TIR) at 34 weeks of gestation
Time frame: 34 weeks of gestation
Glycemic control as measured by time in range (TIR) acquired from retrospective continuous glucose monitoring devices (r-CGM) at 34 weeks of gestation among women with type 2 diabetes mellitus.
23 secondary outcomes
Glycosylated hemoglobin (HbA1c) and glycosylated serum albumin
Time frame: 24, 28, 34 weeks of gestation and 6 weeks of postpartum
TIR calculated by patients' SMBG data
Time frame: At 4 weeks after randomization, and at 24, 28, 34 and 38 weeks of gestation
TAR and TBR
Time frame: At 24, 28 and 34 weeks of gestation
Blood glucose fluctuation index
Time frame: At 24, 28 and 34 weeks of gestation
The AUC of blood glucose within 24 hours before delivery
Time frame: Within 24 hours before delivery
Hypoglycemic events
Time frame: From randomization, up to 42 weeks of gestation
Insulin requirements
Time frame: 4 weeks after randomization, 24, 28, 34 weeks of gestation and 6 weeks of postpartum.
Hypertension during pregnancy
Time frame: From randomization, up to 42 weeks of gestation
Caesarean sections at delivery
Time frame: At delivery
Gestational weight gain
Time frame: 24, 28, 34 weeks of gestation and 6 weeks of postpartum
Maternal hospital stay
Time frame: From admission to discharge from hospital due to delivery
Infant birthweight
Time frame: At delivery
Pregnancy loss
Time frame: From randomization, up to 28 days after delivery
Infant Outcomes (Gestational week of delivery)
Time frame: At birth
Infant Outcomes (Apgar score)
Time frame: At birth
Infant Outcomes (Up to first 7 days of infants' life)
Time frame: Up to first 7 days of infants' life
Infant Outcomes (Up to f first 7 days of life)
Time frame: Up to first 7 days of infants' life
The composite endpoint of infants
Time frame: Up to first 7 days of infants' life
Questionnaires (WHO-5 physical and mental health index)
Time frame: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-manage behavior scale)
Time frame: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-efficacy scale for diabetes mellitus)
Time frame: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-rated Anxiety Scale, SAS)
Time frame: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Questionnaires (Self-rated Depression Scale, SDS)
Time frame: At randomization, 34 weeks of gestation and 6 weeks of postpartum
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2021.
- Individual participant dataSharing planned: No. Other researchers can contact the research group for IPD only for academic research, after the ethics committee re-evaluation and determination that the data transmission did not cause privacy disclosure to patients.
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous subcutaneous insulin infusion (CSII) and Multiple daily insulin injection (MDI) in people with Type 2 Diabetes and Pregnancy in Diabetic, run by Peking University Third Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Haining Wang, MD and Ph.D (+86-18211087263, hainingmail@bjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time in range (TIR) at 24 weeks of gestation (time frame: 24 weeks of gestation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2021.